Please use this identifier to cite or link to this item: http://archive.cmb.ac.lk:8080/xmlui/handle/70130/5457
Full metadata record
DC FieldValueLanguage
dc.contributor.authorJayawardene, N.K.P.S-
dc.contributor.authorSooriyarachchi, M.R.-
dc.date.accessioned2021-07-07T03:24:37Z-
dc.date.available2021-07-07T03:24:37Z-
dc.date.issued2009-
dc.identifier.citationN.K.P.S. Jayawardana and M.R. Sooriyarachchi ‘Prognostic models with competing risks : Methods and Application to Prostate Cancer data’ Sri Lankan Journal of Applied Statistics (2009). Volume 10 pages 43-64en_US
dc.identifier.urihttp://archive.cmb.ac.lk:8080/xmlui/handle/70130/5457-
dc.description.abstractFundamental statistical methods for analyzing competing risks data have been in discussion for decades. However there’s still an uncertainty on how to approach this type of data due to its complexities and thus there exist several gaps in the available methodology particularly in the area of modeling and model validation. Hence, this has become a topic of interest for many researchers. We review competing-risk regression models with a view toward: testing for prognostic factors, testing for treatment effects after adjusting for prognostic factors and model validation. . An example of prostate cancer data from a French study is used to illustrate the methods examined. This includes the application of the Lunn and McNeil regression model for testing prognostic factors and treatments and the adaptation and modification of a goodness-of-fit test, suggested in the literature, to test the hypothesis whether to include the covariates in a multiplicative Cox proportional hazards model, against the hypothesis whether to include the covariates in a more general class of additive-multiplicative model. Serum prostatic acid phosphatase, Combined index of stage and histological grade, Size of primary tumor, Serum hemoglobin level, Performance rating and age were identified as the more vital factors for the survival of patients from death by prostate cancer. Furthermore, the active treatments (estrogen) significantly effects time to death by prostate cancer, where the survival experience of patients showed improvement for higher doses of estrogen treatment. The goodness of fit test indicated that the model fit was adequate and that all prognostic factors in the model had a multiplicative effect on hazard.en_US
dc.description.sponsorshipNo sponsorsen_US
dc.language.isoenen_US
dc.publisherIASSLen_US
dc.subjectCompeting Risks, Cumulative Incidence Function, Proportional Hazards, Stratified Cox model, Additive-Multiplicative Hazards Model.en_US
dc.titlePrognostic models with competing risks : Methods and Application to Prostate Cancer dataen_US
dc.typeArticleen_US
Appears in Collections:Department of Statistics

Files in This Item:
File Description SizeFormat 
Jayawardana_Sooriyarachchi_IC2010.pdf290.32 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.